-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, COMPASS Pathways announced that it is developing psilocybin therapy COMP360 and has reached the primary endpoint in a Phase 2b clinical trial for the treatment of patients with refractory depression
Depression that fails after two or more antidepressant treatments is called treatment refractory depression (TRD)
Psilocybin (psilocybin) is a hallucinogenic active ingredient derived from poisonous mushrooms.
In this trial, 233 patients with refractory depression received three doses of COMP360 at random, accompanied by psychological support provided by professional therapists
The results of the test showed that at the third week, the 25 mg group had a lower MADRS depression scale score than the 1 mg group by 6.
▲The primary endpoint efficacy results of COMP360 (Image source: COMPASS Pathways official website)
In addition, at week 12, 24.
In terms of safety, COMP360 is generally well tolerated, and more than 90% of the adverse events (TEAE) after treatment are mild or moderate in severity
Note: The original text has been deleted
Reference materials:
[1] COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression.
